Gene · 25913
NIH grants1,830
NIH grants whose papers are about the gene, through NIH's grant-paper links.
961 to 980 of 1,830
Download this page as JSON| Grant | Title | POT1 papers | Newest fiscal year |
|---|---|---|---|
| P20CA210300 | Regional Center of Research Excellence in Cancer and Other Non-Communicable Disease Epidemiology and Prevention in Vietnam | 1 | 2017 |
| P30DK072506 | Basic and Translational Studies of Cystic Fibrosis | 1 | 2017 |
| P30GM106396 | Molecular Targets Phase III CoBRE | 1 | 2017 |
| P41GM103314 | National Resource for Mass Spectrom of Biological Macromolecules | 1 | 2017 |
| P50CA168505 | The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE | 1 | 2017 |
| R01AG042611 | Pleiotropic and Interaction Effects on Alzheimer's disease Risk and Progression | 1 | 2017 |
| R01AG043930 | Translational Systems Genetics of Mitochondria, Metabolism, and Aging | 1 | 2017 |
| R01CA077325 | Double-Strand Break Repair and Genome Stability | 1 | 2017 |
| R01CA088932 | Regulation of Telomerase by Sphingolipid Signaling in Lung Cancer | 1 | 2017 |
| R01CA138688 | Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co | 1 | 2017 |
| R01CA142873 | The GNAQ pathway as a therapeutic target in uveal melanoma | 1 | 2017 |
| R01CA163722 | Defining mechanisms of extracellular communication for cancer therapy | 1 | 2017 |
| R01CA169316 | Imaging Guided Genomics of Malignant Transformation | 1 | 2017 |
| R01CA171972 | Targeted Elimination of Cancer Stem Cells for AML Therapy | 1 | 2017 |
| R01CA172380 | Determining the Roles of ATRX and DAXX Abnormalities in Cancer Telomere Biology | 1 | 2017 |
| R01CA174942 | The role of histone chaperone Asf1 in Alternative Lengthening of Telomeres | 1 | 2017 |
| R01CA175086 | MutT Homolog 1 as a Novel Mediator of RAS Oncogene-Induced Pro-Malignant Pathways | 1 | 2017 |
| R01CA177319 | The Role of NOTCH1 in the Pathogenesis of CLL. | 1 | 2017 |
| R01CA177734 | Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas | 1 | 2017 |
| R01CA185363 | (PQC2)Nanoscale changes in 3D nuclear architecture during breast tumorigenesis | 1 | 2017 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25913/grants?page=49